FindTrial
Sign In

The role of EZH2 in the progression of peritoneal fibrosis in peritoneal dialysis patients

The role of EZH2 in the progression of peritoneal fibrosis in peritoneal dialysis patients

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800015272
Enrollment
Unknown
Registered
2018-03-19
Start date
2018-04-01
Completion date
Unknown
Last updated
2018-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

peritonitis

Interventions

Case series:No

Sponsors

Shanghai East Hospital Affiliated to Tongji University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 98 Years

Inclusion criteria

Inclusion criteria: The duration of peritoneal dialysis is 3 to 24 months and the patient is stable for at least 3 months

Exclusion criteria

Exclusion criteria: Peritonitis, severe heart failure, unstable angina pectoris, active liver disease, trauma and surgery in the last 1 month

Design outcomes

Primary

MeasureTime frame
EZH2;—

Countries

China

Contacts

Public ContactNa Liu

Shanghai East Hospital Affiliated to Tongji University School of Medicine

naliubrown@163.com+86 18217768587

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026